iNtRON Biotechnology Inc (048530) — Cash Flow-to-Debt Ratio
iNtRON Biotechnology Inc (048530) has a Cash Flow-to-Debt Ratio of -0.21x as of September 2025, meaning its operating cash flow of ₩-993.53 Million could theoretically repay 0% of its total liabilities (₩4.73 Billion) in one year. See 048530 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
iNtRON Biotechnology Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for iNtRON Biotechnology Inc across 11 annual periods. Also explore net asset momentum of iNtRON Biotechnology Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for iNtRON Biotechnology Inc (2012–2024)
Year-by-year debt coverage analysis for iNtRON Biotechnology Inc. For market capitalisation and broader financial context, see 048530 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.05x | ₩-138.47 Million | ₩2.60 Billion | ▼ -103.2% |
| 2023 | 1.66x | ₩3.12 Billion | ₩1.88 Billion | ▲ +864.7% |
| 2022 | 0.17x | ₩5.98 Billion | ₩34.78 Billion | ▼ -45.7% |
| 2021 | 0.32x | ₩16.47 Billion | ₩52.02 Billion | ▼ -32.7% |
| 2020 | 0.47x | ₩7.13 Billion | ₩15.16 Billion | ▲ +1493.7% |
| 2019 | -0.03x | ₩-812.48 Million | ₩24.07 Billion | ▼ -112.6% |
| 2018 | 0.27x | ₩4.20 Billion | ₩15.70 Billion | ▲ +175.3% |
| 2017 | -0.36x | ₩-5.47 Billion | ₩15.38 Billion | ▲ +20.0% |
| 2016 | -0.44x | ₩-4.64 Billion | ₩10.46 Billion | ▼ -255.0% |
| 2015 | 0.29x | ₩1.70 Billion | ₩5.93 Billion | ▲ +768.1% |
| 2012 | -0.04x | ₩-331.01 Million | ₩7.72 Billion | — |